Histology
Adenocarcinoma
CI-CAN-00000403Explore in graph →
2,753 active trials43 approved drugs423 evidence items
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00000403Explore in graph →
Clinical trials
9,703 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,319)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01231399 | Everolimus and Combination Chemotherapy in Treating Patients With Metastatic Stomach or Esophageal Cancer | completed | Phase 1 / Phase 2 | 6 | City of Hope Medical CenterOTHER | 1 | May 31, 2017 | clinicaltrials |
| NCT00835978 | Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer | completed | Phase 2 | 213 | PfizerINDUSTRY | 6 | May 30, 2017 | clinicaltrials |
| NCT00791037 |
| Vaccine Therapy in Treating Patients With Stage IV Breast Cancer |
| completed |
| Phase 1 / Phase 2 |
| 23 |
| University of WashingtonOTHER |
| 1 |
| May 25, 2017 |
| clinicaltrials |
| NCT00170157 | Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer | completed | Phase 2 | 112 | Mayo ClinicOTHER | 1 | May 15, 2017 | clinicaltrials |
| NCT00366457 | Gemcitabine, Bevacizumab and Erlotinib in Pancreatic Cancer | completed | Phase 2 | 32 | Massachusetts General HospitalOTHER | 1 | May 15, 2017 | clinicaltrials |
| NCT00307736 | Bevacizumab, Erlotinib and 5-Fluorouracil With External Beam Radiation Therapy in Locally Advanced Rectal Cancer | completed | Phase 1 / Phase 2 | 32 | Massachusetts General HospitalOTHER | 1 | May 10, 2017 | clinicaltrials |
| NCT01462214 | Study of Everolimus and Low-dose Cyclophosphamide in Patients With Metastatic Renal Cell Cancer | completed | Phase 1 / Phase 2 | 96 | Hans J. van der Vliet, MD, PhDOTHER | 1 | May 10, 2017 | clinicaltrials |
| NCT01357486 | Palliative Treatment of Hepatocellular Carcinoma in Patient With CHILD B Cirrhosis(PRODIGE 21) | completed | Phase 2 | 160 | University Hospital, BordeauxOTHER | 1 | May 1, 2017 | clinicaltrials |
| NCT01228084 | Sulforaphane in Treating Patients With Recurrent Prostate Cancer | completed | Phase 2 | 20 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 28, 2017 | clinicaltrials |
| NCT01306032 | Phase II ABT-888 With Cyclophosphamide | completed | Phase 2 | 124 | National Cancer Institute (NCI)NIH | 2 | Apr 26, 2017 | clinicaltrials |
| NCT00519896 | Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer | completed | Phase 2 | 35 | University of WashingtonOTHER | 1 | Apr 25, 2017 | clinicaltrials |
| NCT01514526 | Clinical Trial of Dovitinib in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical Carcinoma | completed | Phase 2 | 17 | Spanish Oncology Genito-Urinary GroupOTHER | 1 | Apr 25, 2017 | clinicaltrials |
| NCT00095563 | Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Apr 18, 2017 | clinicaltrials |
| NCT00118092 | 17-AAG in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy | completed | Phase 2 | 17 | National Cancer Institute (NCI)NIH | 1 | Apr 18, 2017 | clinicaltrials |
| NCT00971620 | Randomized Pilot Study for the Treatment of Cutaneous Leiomyomas With Botulinum Toxin | completed | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | Apr 7, 2017 | clinicaltrials |
| NCT00244764 | GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma | completed | Phase 2 | 225 | GlaxoSmithKlineINDUSTRY | 8 | Mar 27, 2017 | clinicaltrials |
| NCT00719264 | Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer | completed | Phase 2 | 365 | Novartis PharmaceuticalsINDUSTRY | 21 | Mar 20, 2017 | clinicaltrials |
| NCT00322361 | Modified Process Hepatitis B Vaccine in Healthy Neonates (V232-056) | completed | Phase 2 | 566 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Mar 16, 2017 | clinicaltrials |
| NCT00729157 | Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy | completed | Phase 2 | 41 | National Cancer Institute (NCI)NIH | 1 | Mar 15, 2017 | clinicaltrials |
| NCT00630409 | Phase II Clinical Trial of Gemcitabine and Doxil® for Metastatic Renal Cell Carcinoma | completed | Phase 2 | 5 | University of PittsburghOTHER | 1 | Mar 10, 2017 | clinicaltrials |
| NCT01141569 | A Study of RO4929097 in Patients With Advanced Renal Cell Carcinoma That Have Failed Vascular Endothelial Growth Factor (VEGF)/Vascular Endothelial Growth Factor Receptor (VEGFR) Therapy | completed | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Mar 10, 2017 | clinicaltrials |
| NCT01522937 | A Study of Individualized Stereotactic Body Radiation Therapy (SBRT) for Intrahepatic Cancer | completed | Phase 2 | 94 | University of Michigan Rogel Cancer CenterOTHER | 1 | Mar 9, 2017 | clinicaltrials |
| NCT01507064 | Neoadjuvant Sorafenib Therapy Prior to Laser Ablation for Hepatocellular Carcinoma(LANEX) | completed | Phase 2 | 40 | Cardarelli HospitalOTHER | 1 | Mar 7, 2017 | clinicaltrials |
| NCT00617253 | Combination of Recombinant Human IL-21 (rIL-21) and Sunitinib in Stage IV Renal Cell Carcinoma Patients | completed | Phase 2 | 9 | Novo Nordisk A/SINDUSTRY | 2 | Mar 1, 2017 | clinicaltrials |
| NCT01576380 | A Phase II Study to Evaluate Efficacy and Safety of Dovitinib (TKI258) in Advanced Scirrhous Gastric Carcinoma Patients | completed | Phase 2 | 11 | Novartis PharmaceuticalsINDUSTRY | 1 | Feb 27, 2017 | clinicaltrials |
| NCT02607553 | Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMA | completed | Phase 2 | 2 | GenSpera, Inc.INDUSTRY | 1 | Feb 24, 2017 | clinicaltrials |
| NCT00058084 | Ixabepilone Compared With Mitoxantrone and Prednisone in Treating Patients With Refractory Metastatic Prostate Cancer | completed | Phase 2 | 80 | National Cancer Institute (NCI)NIH | 1 | Feb 23, 2017 | clinicaltrials |
| NCT00118248 | Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer | completed | Phase 2 | 41 | National Cancer Institute (NCI)NIH | 1 | Feb 15, 2017 | clinicaltrials |
| NCT01273662 | Axitinib as Second-line Treatment for Advanced Hepatocellular Carcinoma | completed | Phase 2 | 45 | National Taiwan University HospitalOTHER | 1 | Feb 9, 2017 | clinicaltrials |
| NCT03048123 | HAIC Versus TACE for Large and Unresectable Hepatocellular Carcinoma Staged BCLC A/B | completed | Phase 2 | 79 | Sun Yat-sen UniversityOTHER | 1 | Feb 9, 2017 | clinicaltrials |
| NCT00273312 | Patupilone Activity in Advanced/Metastatic Hepatocellular Carcinoma | completed | Phase 2 | 25 | Novartis PharmaceuticalsINDUSTRY | 4 | Feb 7, 2017 | clinicaltrials |
| NCT00361231 | Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Biliary Tract and Gallbladder Cancer | completed | Phase 2 | 35 | Massachusetts General HospitalOTHER | 1 | Feb 7, 2017 | clinicaltrials |
| NCT00516165 | RAD001 in Advanced Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 28 | Massachusetts General HospitalOTHER | 1 | Feb 7, 2017 | clinicaltrials |
| NCT02447679 | Oral Thalidomide and Tegafur-uracil to Decrease Hepatocellular Carcinoma Recurrence | completed | Phase 2 | 40 | Chang Gung Memorial HospitalOTHER | 1 | Feb 7, 2017 | clinicaltrials |
| NCT00423332 | Cediranib (AZD2171, RECENTIN™) in Metastatic or Recurrent Renal Cell Carcinoma | completed | Phase 2 | 105 | AstraZenecaINDUSTRY | 2 | Feb 2, 2017 | clinicaltrials |
| NCT00559949 | Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine | completed | Phase 2 | 39 | National Cancer Institute (NCI)NIH | 2 | Jan 30, 2017 | clinicaltrials |
| NCT02199418 | Addition of Cisplatin to Neoadjuvant Therapy for T Locally Advanced Breast Cancer(SHPD001) | completed | Phase 2 | 132 | RenJi HospitalOTHER | 1 | Jan 25, 2017 | clinicaltrials |
| NCT00256880 | Pazopanib (GW786034) In Subjects With Relapsed Or Refractory Multiple Myeloma | completed | Phase 2 | 100 | GlaxoSmithKlineINDUSTRY | 2 | Jan 18, 2017 | clinicaltrials |
| NCT02334709 | Phase I/II Trial of Stereotactic Body Radiotherapy With Concurrent Fixed Dose Tyrosine Kinase Inhibitors in Metastatic Renal Cell Carcinoma: Dose Limiting Toxicity and Abscopal Effect. | completed | Phase 1 / Phase 2 | 13 | University Hospital, GhentOTHER | 1 | Jan 11, 2017 | clinicaltrials |
| NCT02829775 | A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies | completed | Phase 2 / Phase 3 | 9 | Hoffmann-La RocheINDUSTRY | 7 | Jan 9, 2017 | clinicaltrials |
| NCT00559377 | FDG and FMISO PET Hypoxia Evaluation in Cervical Cancer | completed | Phase 2 | 16 | National Cancer Institute (NCI)NIH | 1 | Dec 30, 2016 | clinicaltrials |
| NCT01294306 | MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy | completed | Phase 2 | 80 | National Cancer Institute (NCI)NIH | 1 | Nov 29, 2016 | clinicaltrials |
| NCT00903175 | Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma(RECORD-3) | completed | Phase 2 | 471 | Novartis PharmaceuticalsINDUSTRY | 19 | Nov 8, 2016 | clinicaltrials |
| NCT01369420 | NanoKnife Low Energy Direct Current (LEDC) System in Subjects With Locally Advanced Unresectable Pancreatic Cancer | completed | Phase 2 | 10 | Angiodynamics, Inc.INDUSTRY | 1 | Nov 8, 2016 | clinicaltrials |
| NCT02576964 | A Study of Capecitabine (Xeloda) and Peginterferon Alfa-2a (Pegasys) in Treatment-Naive Participants With Advanced Liver Cancer | completed | Phase 2 | 16 | Hoffmann-La RocheINDUSTRY | 3 | Nov 2, 2016 | clinicaltrials |
| NCT02562729 | Complete Nerve-Sparing Radical Hysterectomy for Cervical Cancer | completed | Phase 2 | 62 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 1 | Oct 14, 2016 | clinicaltrials |
| NCT00508001 | Phase II Study of Best Support Care (BSC) Plus ZD6474(Vandetanib) in Patients With Inoperable Hepatocellular Carcinoma (HCC) | completed | Phase 2 | 67 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Oct 10, 2016 | clinicaltrials |
| NCT00126594 | Sorafenib Tosylate With or Without Recombinant Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer | completed | Phase 2 | 80 | National Cancer Institute (NCI)NIH | 1 | Sep 16, 2016 | clinicaltrials |
| NCT00688753 | RAPTOR: RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Tumors Program in Europe(MACS0460) | completed | Phase 2 | 92 | Novartis PharmaceuticalsINDUSTRY | 6 | Sep 2, 2016 | clinicaltrials |
| NCT01777594 | Study of G-202 (Mipsagargin) as Second-Line Therapy Following Sorafenib in Hepatocellular Carcinoma(G-202-003) | completed | Phase 2 | 25 | GenSpera, Inc.INDUSTRY | 1 | Aug 23, 2016 | clinicaltrials |
Data updated 23 days agoSource updated May 31, 2017source: clinicaltrials